ArticleFrontiers in oncology2025
Sequential salvage systemic therapy after immunotherapy in head and neck cancer: a real-world study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) there is no established standard therapy after progression to immune checkpoint inhibitors (ICI). Retrospective and limited prospective studies have suggested that salvage chemotherapy after ICI (SCAI) may outperform historical pre-ICI data. We evaluated cetuximab-based SCAI outcomes in a real-world setting. Methods: Objective response rate (ORR), median duration of response (DoR), and median best percentage change in target lesions (PCTL) by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1), and median progression-free survival (PFS) and overall survival (OS) with SCAI and with last chemotherapy before immunotherapy (LCBI) were assessed. Adverse events (AEs) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0 were evaluated during SCAI, as well as treatment exposure to cetuximab-based therapy and to ICI across the whole R/M setting. Results: Among 80 patients, 96% and 100% received cetuximab-based first and second SCAI, respectively, primarily as weekly (90%-94%) regimens, as follows. First SCAI: ORR of 59% (41/70; 31 partial and 10 complete responses), PCTL of -57% (range, -30% to -100%), DoR of 9.4 months, and PFS and OS of 5.9 and 12.4 months, respectively; first-line OS of 24 months. Cetuximab-based exposure (256 days) significantly exceeded ICI exposure (168.5 days; p = 0.038). LCBI-treated (n = 22): ORR of 36% (LCBI) Conclusion: Cetuximab-based SCAI post-ICI showed high rates of response, which were durable and profound, and improved survival compared to historical data, with modest efficacy in re-sequenced patients. Time on cetuximab was significantly longer than on ICI. These results should be confirmed in a larger prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.